A Study of Ninlaro in Real World Clinical Practice in China
Completed
482 enrolled
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Phase 2 Completed
39 enrolled 15 charts
FT576 in Subjects With Multiple Myeloma
Phase 1 Completed
31 enrolled
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Completed
633 enrolled 15 charts
MargheRITA
Phase NA Completed
124 enrolled
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
Completed
514 enrolled 16 charts
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Phase 1/2 Completed
18 enrolled
A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Completed
78 enrolled
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
Completed
508 enrolled 16 charts
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1/2 Completed
95 enrolled 13 charts
Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyricâ„¢ Flow Cytometer
Completed
208 enrolled
A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
18 enrolled
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Phase 3 Completed
1,718 enrolled 22 charts
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
Phase 1 Completed
26 enrolled
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Phase 3 Completed
637 enrolled 15 charts
Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
Phase 1 Completed
62 enrolled
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
Phase 1 Completed
46 enrolled
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Completed
79 enrolled
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
Phase 1 Completed
15 enrolled
REVIEW
Completed
238 enrolled
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
34 enrolled
PANORAMA-1
Phase 3 Completed
767 enrolled 17 charts
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Phase 3 Completed
74 enrolled 17 charts
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
Phase 1 Completed
38 enrolled
AMBER
Phase 2 Completed
102 enrolled 13 charts
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Phase 1 Completed
48 enrolled 26 charts
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase 2 Completed
50 enrolled 33 charts
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
Phase 1 Completed
21 enrolled
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
Phase 2 Completed
100 enrolled
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Phase 1/2 Completed
70 enrolled
Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma
Phase 1 Completed
20 enrolled
Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
Phase 1 Completed
40 enrolled
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Phase 1 Completed
20 enrolled 6 charts
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Phase 1 Completed
30 enrolled
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Phase 1 Completed
30 enrolled
Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support
Phase 1 Completed
25 enrolled
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
Phase 2 Completed
53 enrolled
P05538
Phase 1 Completed
41 enrolled
AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Completed
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Phase 1 Completed
50 enrolled
Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
Phase 2 Completed
62 enrolled
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
Phase 1 Completed
40 enrolled
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
Phase 2 Completed
51 enrolled 10 charts
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
Completed
801 enrolled
Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
Phase 2 Completed
220 enrolled
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 2 Completed
25 enrolled